JDD April 2025 Issue Highlights: Innovation, Inclusion & Insight in Dermatology
This month’s Journal of Drugs in Dermatology issue is packed with groundbreaking studies and real-world insights spanning across age groups, skin types, and therapeutic categories. From improving dermatoporosis in older adults to exploring an acne management algorithm that smartly integrates acneceuticals, the April Editor’s Picks reflect dermatology’s evolving landscape. Highlights include a look into patient …
Continue reading “JDD April 2025 Issue Highlights: Innovation, Inclusion & Insight in Dermatology”
JDD Buzz Series | Social Media’s Impact on Hair Loss Information
Social media is a major source of medical information, including information about hair loss. How reliable is the hair loss material presented on social media, and how does this information impact patients? Those are some of the questions posed by researchers in a study published in the March Journal of Drugs in Dermatology. I interviewed …
Continue reading “JDD Buzz Series | Social Media’s Impact on Hair Loss Information”
JDD March 2025 Editor’s Picks
Get ready to explore the latest advancements in dermatology with the March issue of the Journal of Drugs in Dermatology! This edition dives deep into cutting-edge research, including AI-driven personalized hair loss treatments, the dermatologic potential of berberine, and the evolving role of social media in hair loss education. Plus, don’t miss insights on acneceuticals, …
JDD Buzz Series | Sunscreens: Mechanisms and Safety in Depth
Despite decades of educational efforts, there is growing public skepticism over sunscreen’s safety and efficacy. Researchers from Chicago sought to synthesize the current scientific understanding of sunscreen in order to help dermatology clinicians address concerns. The findings are published in the February Journal of Drugs in Dermatology. I interviewed author Natalia Chalupczak, medical student at …
Continue reading "JDD Buzz Series | Sunscreens: Mechanisms and Safety in Depth"
JDD February 2025 Editor’s Picks
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis. Readers will also discover updates …
JDD Buzz Series | Diversity in Melasma Clinical Trials
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation. I interviewed author …
Continue reading “JDD Buzz Series | Diversity in Melasma Clinical Trials”
Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patient with vitiligo, is thought to be decreased. This report presents a case of melanoma developing on a non-sun-exposed site in a patient with …
Continue reading “Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color”
JDD January 2025 Editor’s Picks | Special Focus: Aesthetic Treatments
Welcome to the first issue of the Journal of Drugs in Dermatology for 2025! This issues focuses on the exciting advancements in aesthetic treatments, with editor’s picks that delve into cutting-edge topics shaping dermatology today. From the role of exosomes in cosmetic dermatology to expert insights on managing neuromodulator complications, this issue offers invaluable guidance …
Continue reading “JDD January 2025 Editor’s Picks | Special Focus: Aesthetic Treatments”
JDD Buzz Series | Metformin’s Potential Chemopreventive Effect
A commonly used diabetes medication may help prevent non-melanoma skin cancer. A study in the December Journal of Drugs in Dermatology analyzed whether metformin exposure is associated with a reduced risk of non-melanoma skin cancer. The study also stratified findings by race/ethnicity, which makes it unique among similar research studies. I interviewed author Tiffany Jow …
Continue reading “JDD Buzz Series | Metformin’s Potential Chemopreventive Effect”
Hyperpigmented Macules and Patches on the Face: Exogenous Ochronosis or Lichen Planus Pigmentosus?
JDD authors Deepika Narayanan, MD and Stephen K. Tyring, MD, PhD, MBA present a case of a patient with a 10-year history of blue-black macules and patches on the face and an associated history of skin- lightening cream usage. The skin lightening cream contained hydroquinone, which is often associated with exogenous ochronosis (EO). Interestingly, the …